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IMPORTANCE A substantial number of patients diagnosed with high-risk prostate cancer are
at risk for metastatic progression after primary treatment. Better biomarkers are needed to
identify patients at the highest risk to guide therapy intensification.
OBJECTIVE To create a DNA damage and repair (DDR) pathway profiling method for use as a
prognostic signature biomarker in high-risk prostate cancer.
DESIGN, SETTING, AND PARTICIPANTS A cohort of 1090 patients with high-risk prostate cancer
who underwent prostatectomy and were treated at 3 different academic institutions were
divided into a training cohort (n = 545) and 3 pooled validation cohorts (n = 232, 130, and
183) assembled for case-control or case-cohort studies. Profiling of 9 DDR pathways using 17
gene sets for GSEA (Gene Set Enrichment Analysis) of high-density microarray gene
expression data from formalin-fixed paraffin-embedded prostatectomy samples with median
10.3 years follow-up was performed. Prognostic signature development from DDR pathway
profiles was studied, and DDR pathway genemutation in published cohorts was analyzed.
MAIN OUTCOMES ANDMEASURES Biochemical recurrence-free, metastasis-free, and overall
survival.
RESULTS Across the training cohort and pooled validation cohorts, 1090menwere studied;
mean (SD) age at diagnosis was 65.3 (6.4) years. We found that there are distinct clusters of
DDR pathways within the cohort, and DDR pathway enrichment is only weakly correlated
with clinical variables such as age (Spearman ρ [ρ], range, −0.07 to 0.24), Gleason score
(ρ, range, 0.03 to 0.20), prostate-specific antigen level (ρ, range, −0.07 to 0.10), while 13 of
17 DDR gene sets are strongly correlated with androgen receptor pathway enrichment
(ρ, range, 0.33 to 0.82). In published cohorts, DDR pathway genes are rarely mutated. A DDR
pathway profile prognostic signature built in the training cohort was significantly associated
with biochemical recurrence-free, metastasis-free, and overall survival in the pooled
validation cohorts independent of standard clinicopathological variables. The prognostic
performance of the signature for metastasis-free survival appears to be stronger in the
younger patients (HR, 1.67; 95% CI, 1.12-2.50) than in the older patients (HR, 0.77; 95% CI,
0.29-2.07) onmultivariate Cox analysis.
CONCLUSIONS AND RELEVANCE DNA damage and repair pathway profiling revealed
patient-level variations and the DDR pathways are rarely affected bymutation. A DDR
pathway signature showed strong prognostic performance with the long-term outcomes of
metastasis-free and overall survival that may be useful for risk stratification of high-risk
prostate cancer patients.
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O ver29000mendie fromprostate cancer annually,de-spite themajority being diagnosedwith clinically lo-calized disease when cure is still likely.1,2 Therefore,
there is a critical need to identify this subset with potentially
lethal localized disease within the 220000 men diagnosed
each year. Current clinical paradigms using prostate-specific
antigen (PSA) level, Gleason score, and tumor stage, provide
guidance but are imperfect.3,4 Molecular biomarkers are an
emerging strategy to identify patientswith prostate cancer at
high risk of metastatic progression from those at reduced or
standard risk.5-7
Biomarker studieshaveevolved fromsingle-gene,hypoth-
esis-drivenstudies tounbiasedgenebiomarkernominationand
signature development.7-10 Several analyses have taken a hy-
brid pathway-based approach focused on DNA repair path-
ways based on its central role in radiotherapy and chemo-
therapy response. These DNA repair pathway scores have
prognostic and/or predictive power in lung and ovarian
cancer.11,12 Inprostate cancer, no suchanalyseshavebeenper-
formed, anda lackof gene expressiondatawith long-term fol-
low-up hampers biomarker studies in general.
Wehypothesized thatDNAdamageand repair (DDR)path-
ways hold prognostic information in prostate cancer and de-
veloped a novel patient-level DDR pathway profiling ap-
proach to investigate this.We applied this approach to a large
prostatectomy cohortwith long clinical follow-up that allows
for analysis of robust outcomes of biochemical recurrence-
free, metastasis-free, and overall survival. We assessed cor-
relationbetweenDDRpathwaysandmolecular or clinical vari-
ables and used multivariate analysis to build and validate a
prognostic signature biomarker combining the DDR path-
ways. Overall, this study investigates the potential for indi-
vidualized DDR pathway profiling in the clinical manage-
ment of prostate cancer.
Methods
Study Design and Tissue Samples
Tumor samples were from 4 published retrospective prosta-
tectomy patient cohorts at the Mayo Clinic (MCI and MCII),
Cleveland Clinic (CC), and Thomas Jefferson University
(TJU).5-7,13 Informed consent protocols were approved by lo-
cal institutional reviewboards. TheMCI6 cohortwas a nested
case-control studywith 545men inmatched triplets ofmeta-
static progression, biochemical recurrence without meta-
static progression, andnoevidence of disease after prostatec-
tomy. The MCII7 cohort was a metastatic progression case
cohort study of 1010 men sampled to generate a final cohort
of 232. The TJU5 cohort is comprised of 130 patients who un-
derwent postoperative radiotherapy for pT3 or margin-
positive disease at prostatectomy. TheCCcohort included 183
patients from a 3:1 no evidence of disease to metastatic pro-
gression sampling ratio from a case-control study of 2317 pa-
tients who underwent prostatectomy with preoperative PSA
greater than 20 ng/mL, pT3, positive margins, or pathologic
Gleason score of 8 or higher who did not receive adjuvant or
neoadjuvant therapy.13Treatmentafterprostatectomy, includ-
ing androgen deprivation therapy and/or radiotherapy, was
given for disease recurrence at the discretion of the treating
physician in all cohorts. Patients in all cohorts were followed
formultipleoutcomes includingbiochemical recurrence,meta-
static progression, and any death.
Tissue Preparation, RNA Extraction,
andMicroarray Hybridization
As described previously, formalin-fixed paraffin embedded
(FFPE) prostatectomy samples were collected from the 4
cohorts.5-7 RNA extraction andmicroarray hybridization was
performedinaCLIA(ClinicalLaboratory ImprovementAmend-
ments)-certified, clinical operations laboratory (GenomeDx
Biosciences, Inc). Purified totalRNAwaswhole-transcriptome
amplified using theWT-Ovation FFPE system (NuGen), frag-
mented and labeled using the Encore Biotin Module
(NuGen), and hybridized to Affymetrix Human Exon (HuEx)
1.0 STGeneChips (Affymetrix).Microarraynormalizationwas
done with single channel array normalization, and quality
control was performed using Affymetrix Power Tools
(Affymetrix, Inc). Gene expression was calculated using
Affymetrix Core-level summaries for annotated genes as
previously described. Microarray data are available with
National Center for Biotechnological Information Gene Ex-
pression Omnibus accession numbers GSE46691, GSE62116,
GSE72291, and GSE62667.5-7
Pathway Profiling and GSEA (Gene Set Enrichment Analysis)
We first ensured all expression valueswere positive by adding
a small positive value (4) equal to the lowest negative expres-
sion value as previously described.13 Expression values were
then median-scaled and ranked across all patients on a gene-
by-gene basis. Individual patient gene rank profiles were used
as input for the Gene Set Enrichment Analysis (GSEA) pre-
ranked algorithm with 1000 permutations to generate indi-
vidual patient DDR gene set profiles of normalized enrich-
mentscores.14,15TheGSEAgenesetsusedrepresentedthemajor
DDRpathways in thestandardcuratedpathwaycollectionsBio-
Carta,KEGG(KyotoEncyclopediaofGenesandGenomes), and
Key Points
Question: Can 9 DNA damage and repair (DDR) pathways using 17
gene sets from prostatectomy samples identify better biomarkers
for patients at the highest risk to guide therapy intensification?
Findings:We developed a novel patient-level Gene Set
Enrichment Analysis–based pathway profiling approach and
applied it to high-risk prostatectomy tumor samples from 1090
men using DDR pathways. The DDR pathway profiles correlate
with AR and ERG levels and the AR pathwaymolecular variables
and do not correlate with clinical variables including age, Gleason
score, or prostate-specific antigen level. A DDR pathway signature
trained in a cohort of 545 patients significantly associated with
biochemical recurrence-free, metastasis-free, and overall survival
in 545 additional patients pooled from 3 validation cohorts.
Meaning:DNA damage and repair pathway profiling may be a
useful tool in themanagement of high-risk prostate cancer.
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Reactome found at the GSEA mSigDB web site (http://www
.broadinstitute.org/gsea/msigdb/index.jsp) (eTable 1 in the
Supplement). Multiple gene sets for the same pathway were
combinedbyusing themeantogenerate the followingpathway
scores: DNA damage checkpoint (Checkpoint), DNA repair
(Repair), base excision repair (BER), double-stranded break
repair (DSB), nonhomologous end-joining repair (NHEJ),
mismatch repair (MMR), andnucleotide excision repair (NER);
thehomologousrecombinationgenesetswereusedindividually
(eTable 1 in the Supplement), and androgen receptor pathway
activity was similarly assessed using the “ANDROGEN
_RECEPTOR_SIGNALING_PATHWAY” GSEA gene set.
Mutation Analysis
Primary nonmetastatic prostate genomic profiles from pub-
lishedstudies andTheCancerGenomeAtlasunpublisheddata
were analyzed using the R API from cBioPortal with a custom
script (eMethods in the Supplement).
Statistical Analysis and Signature Generation
CorrelationbetweenDDRgeneset enrichmentandclinical and
molecular variableswas performedwith the Spearman corre-
lation. Univariate analysis (UVA) and multivariate analysis
(MVA) for signature development and determining prognos-
tic association were performed using Cox proportional haz-
ards regression.For signaturedevelopment,DDRpathwaypro-
file scores were used as continuous variables. A threshold for
“high risk” was automatically chosen as the percentile that
minimizes the UVA P value for metastatic progression in the
training cohortMCI. “Cohort”was a stratification variable for
analysis of the pooled validation cohorts (MCII, CC, and TJU)
with different study designs, as described previously.13 Glea-
son score and PSA level were included as categorical vari-
ables basedon risk group criteria: Gleason6andPSA less than
10were considered low risk; Gleason 7 and PSA 10 to 20were
considered intermediate risk; and Gleason 8 to 10 and PSA
greater than 20 were considered high risk. Other clinical co-
variates includedwere lymphnode invasion, extracapsular ex-
tension, seminal vesicle invasion, surgicalmargin status, and
patient age. Outcomes were also analyzed by Kaplan-Meier
analysis with log-rank test. Heatmaps were generated using
R package heatmap.2 with default column scaling. All analy-
ses were performed using R 2.15.
Results
Demographics
The demographics of the 1090 patients across 4 cohorts are
listed in eTable 2 in the Supplement. Themean (SD) age at di-
agnosis was 65.3 (6.4) years. Commensurate with the high-
risk nature of the cohorts, there are substantial rates of high-
risk preoperative features, including 30% to 46% of patients
with PSA greater than 10 ng/mL, 25% to 43%of tumorswith a
Gleason score of 8 to 10, and high rates of pathological high-
risk features, including extracapsular extension in41% to81%
andpositivemargins in 49% to 76%.Median follow-up across
all cohortswas 10.3years, andmetastaticprogression ratesvar-
ied among the cohorts from 8% to 39%. Thus, the large num-
ber of patients and long clinical follow-upmake this is a pow-
erful data set for exploring molecular biomarkers of disease
progression risk in prostate cancer.
Pathway Profiling
We developed a novel patient-level pathway profiling ap-
proach to investigate the prognostic relevance of DDR path-
ways in prostate cancer. Our pathway profiling procedure is
described indetail in the eMethods in theSupplement andde-
picted inFigure 1AandB.Briefly, theGSEAalgorithmwasused
to convert gene expression data into DDR pathway expres-
sion data individually for each patient. Canonical DDR path-
waygenesets fromthecuratedcollectionsBioCarta,KEGG,and
Reactome were used as a fair representation of these path-
ways (eTable 1 in the Supplement). Separately, we found that
the prevalence ofmutations in theDDR gene set genes across
630 primary nonmetastatic prostate samples from published
studies and The Cancer Genome Atlas unpublished data was
less than2%forall genesexcept forATM (3%)andTP53 (6.8%),
indicating that the DDR pathways are negligibly disrupted by
mutation (eTable 3 in the Supplement).
DNA damage and repair pathway profiling was applied
across all 1090 patients. Unsupervised hierarchical cluster-
ing of patient-level DDR pathway enrichment profiles
revealed distinct clusters of patterns of DDR pathway enrich-
ment (Figure 1B). The gene sets representing the same path-
way were highly correlated as expected (Figure 1C). There
was also significant correlation among the pathways, though
the 3 base excision repair gene sets followed an independent
pattern. Of note, the HR pathway gene sets cluster distinctly,
indicating that they capture disparate information. These
findings confirmed our initial hypothesis that there is
patient-level variation in DDR pathways which could carry
prognostic information.
Gene Set Enrichment CorrelationWith Clinical
andMolecular Variables
We then analyzed the correlation of DDR gene set enrich-
mentwith standard clinical andmolecular variables (Figure2)
(eTable 1 and eFigure 1 in the Supplement). Therewas signifi-
cant but weak correlationwith Gleason score for 16 of 17 DDR
gene sets (Spearman rho [ρ], range,0.09 to0.20), andwithage
for 7 of 17 gene sets (ρ, range, −0.07 to 0.24). Prostate-
specific antigen level was weakly correlated with only 3 of 17
genesets (ρ, range,−0.07 to0.10).Thus,DDRgenesetsaregen-
erallyweakly correlatedwith clinical variables, indicating that
DDR pathways can provide independent information.
We also analyzed correlation with the prostate cancer
driver genes AR and ERG (Figure 2) (eTable 1 in the Supple-
ment). AR expression has varying levels of significant posi-
tive correlation with all gene sets (ρ, range, 0.12 to 0.54),
consistent with literature showing AR signaling upregulates
DDR pathways.16,17 As AR messenger RNA (mRNA) expres-
sion may not fully represent AR transcriptional activity, we
also measured AR activity using GSEA, which analyzes
many AR target genes in addition to PSA. Interestingly, cor-
relation between AR activity and the gene sets was stronger
DNADamage and Repair Pathway Profiles and Prostatectomy Original Investigation Research
jamaoncology.com (Reprinted) JAMAOncology April 2016 Volume 2, Number 4 473
Downloaded From: http://jamanetwork.com/pdfaccess.ashx?url=/data/journals/oncology/935166/ by a UCSF LIBRARY User  on 02/28/2017
Copyright 2016 American Medical Association. All rights reserved.
(ρ, up to 0.82). Correlation with ERG expression showed
intermediate results, with 13 of 17 gene sets with significant
correlations (ρ, range, 0.09 to 0.25).
Of note, the homologous recombination gene sets ap-
peared to reflect a distinct pattern. The Reactome homolo-
gous recombination gene set M had a weak positive correla-
tion with AR expression (ρ, 0.12), whereas the KEGG
homologousrecombinationgenesetNhadaweaknegativecor-
relation (ρ, −0.22); results with the AR pathway were simi-
larlydisparate.Wereviewedthese2genesets indetail andcon-
firmedtherearesignificantdifferenceswith9genes incommon
of 17 in Reactomehomologous recombination gene setM and
28 genes in KEGG homologous recombination gene set N
(eTable 4 in the Supplement). Interestingly, neither homolo-
gous recombination gene setwas correlatedwithERG expres-
sion (P > .10 for all). These results demonstrate that the com-
plex interactionsamongtheDDRpathwaysandprostatecancer
molecular drivers that have beenminutely dissected in vitro,
can be assayed in vivo at the individual patient level for pos-
sible use in the clinical management of prostate cancer.
Figure 1. DDR Pathway Profiling Procedure
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Prognostic Performance of Individual Pathways
We next analyzed the prognostic information that might be
contained in the pathway profiles. Seven of the 9 DDR path-
wayshad statistically significant associationswithworseme-
tastasis-free survival on UVA (P < .02 for all) (eTable 5 in the
Supplement). Tocontrol for confounders,weexamined the in-
dividual pathways inMVA.For example, theCheckpointpath-
way, an average of Checkpoint gene sets A through C, had a
statistically significant association with worse metastasis-
free survival (hazard ratio [HR], 1.24; 95%CI, 1.28-1.61). Glea-
son score and seminal vesicle invasionwere also significantly
associated with both outcomes (P < .05 for all), and 5 other
clinical variables were not significant. Gleason score had the
strongest association (HR, 2.42; 95%CI 1.04-5.62 for interme-
diate risk; andHR6.59;95%CI,2.83-15.3 forhighrisk),whereas
seminal vesicle invasion associations were of similar magni-
tude as the Checkpoint pathway. Repeating thisMVA for each
pathway individually revealed that 4 of 9 pathways were sig-
nificantly associated with these outcomes (P < .05 for all).
DDR Pathway Signature
We sought to develop a prognostic signature biomarker
based on combining the DDR pathway profiles consisting of
a multivariate Cox model for metastasis-free survival in the
training cohort MCI. As expected, this DDR pathway signa-
ture was significantly associated with metastasis-free sur-
vival in the training cohort (Figure 3A) but also had signifi-
cant association with biochemical recurrence-free survival
and overall survival (Figure 3C-E). This prognostic associa-
tion was independent of standard clinical variables on MVA
(eTable 6 in the Supplement). In the independent pooled
validation cohorts, the DDR pathway signature was signifi-
cantly associated with biochemical recurrence-free survival
(HR, 1.8; 95% CI, 1.4-2.3) (Figure 3B), metastasis-free sur-
vival (HR, 2.1; 95% CI, 1.5-3.0) (Figure 3D), and overall sur-
vival (HR, 1.8; 95% CI, 1.3-2.5) (Figure 3F). Importantly, these
findings were confirmed to be significant independent of
standard clinicopathological variables on multivariate Cox
analysis, with a concordance index of 0.71 for a model
including the DDR pathway signature and the standard vari-
ables (Table 1) (eTable 7 in the Supplement). In support of
the clinical use of these findings, we have constructed a
nomogram for predicting metastasis-free survival at 10 years
based on these models (eFigure 2 in the Supplement).
Older vs Younger Patients
A recent meta-analysis18 demonstrated that patients older
than 70 years have decreased metastatic progression risk
after radiotherapy for prostate cancer than younger
patients, though a biological explanation remains unclear.
Figure 2. Correlation of DDR Pathway ProfilesWithMolecular Variables
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We surmised that the lack of correlation between age and
the DDR pathways (eTable 1 and eFigure 1C in the Supple-
ment) indicated that the DDR pathways contain indepen-
dent information and could shed light on this differential
outcome by age. We analyzed the performance of the DDR
pathway signature in patients younger than 70 years and 70
years and older in the pooled validation cohorts and found a
difference (Table 2). The prognostic performance of the sig-
nature for metastasis-free survival appears to be stronger in
the younger patients (HR, 1.67; 95% CI, 1.12-2.50) than in
the older patients (HR, 0.77; 95% CI, 0.29-2.07) on multivar-
iate Cox analysis. These results indicate that the DDR path-
ways play a different role in younger vs older patients, and
that this may be responsible for the differential outcome
after radiotherapy.
Analysis by Ethnicity
Ethnicitydatawas collectedonly for 2of the4 cohorts (313pa-
tients), limiting these analyses. In this subset, the propor-
tions of DDR signature low-risk vs high-risk patientswere not
different by ethnicity (Fisher exact test, P = .31) (eTable 8 in
the Supplement). Comparison of mean DDR signature score
Figure 3. Prognostic Performance of the DDR Pathway Signature
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(rawvalues)byethnicitywassimilarly limitedanddidnotshow
a clear difference (eFigure 3 in the Supplement).
Discussion
Thegenomics erahasaffordedanunprecedentedview into tu-
mor biology and the promise of personalized medicine. Un-
biasedexpression studieshavebeenused to identifyprognos-
tic and/orpredictivebiomarkers in the formof individualgenes
or signatures.7-10 However, these analyses generally under-
use thevast amountof biological pathwayknowledge thathas
been accumulated over decades of research. There have been
several attempts at hybrid approaches to develop biomarkers
using large-scale gene expression data with guidance from
pathway knowledge in lung and ovarian cancer.11,12 This ap-
proachhasnot beenpursued inprostate cancer, inwhich long
disease outcome intervals dictate that few data sets with the
mostmeaningful outcomes—metastatic progressionandover-
all survival—are available.
We present a pathway profiling approach in a large pros-
tate cancer cohortwith clinical follow-up long enough to cap-
turemeaningful outcomes. Our approach is based onGSEA, a
well-establishedbioinformatics tool, andoffersanovelmethod
to build a pathway-based biomarker of metastatic progres-
sion risk in prostate cancer.We focused onDDRpathways be-
cause of their central role in response to chemotherapy and
radiotherapy and found that there are clusters of distinctDDR
Table 2. Multivariate Cox Regression Analysis of the DDR Pathway Signature andMetastasis-Free Survival
in 545 Patients in the Pooled Validation Cohorts Stratified by Age
Characteristica
Age
<70 Years ≥70 Years
HR (95% CI) P Value HR (95% CI) P Value
DDR pathway signature, high vs low risk 1.67 (1.12-2.50) .01 0.77 (0.29-2.07) .61
PSA
<10 (Low risk) 1 [Reference] 1 [Reference]
10-20 (Intermediate risk) 1.20 (0.76-1.89) .43 2.10 (0.46-9.48) .34
>20 (High risk) 1.65 (0.97-2.80) .06 3.73 (0.89-15.65) .07
Gleason score
6 (Low risk) 0.13 (0.02-0.94) .04 0.00 (0.00-) >.99
7 (Intermediate risk)b 1 [Reference] 1 [Reference]
8-10 (High risk) 2.17 (1.46-3.23) <.001 2.27 (0.81-6.36) .12
SMS, + vs − 1.07 (0.73-1.59) .72 2.16 (0.70-6.62) .18
SVI 1.34 (0.90-2.02) .15 2.01 (0.71-5.67) .19
ECE 1.77 (1.06-2.95) .03 1.32 (0.40-4.35) .65
LNI 1.35 (0.72-2.54) .35 0.25 (0.03-1.86) .18
Abbreviations: DDR, DNA damage
and repair; ECE, extra-capsular
extension; HR, hazard ratio;
LNI, lymph node involvement;
PSA, prostate specific antigen;
SMS, surgical margin status;
SVI, seminal vesicle invasion.
a The absolute values of each
characteristic can be found in
eTable2 in the Supplement.
bGleason 7 used as reference owing
to a small number of patients with
Gleason 6 in the 70 years or older
subset (n = 4).
Table 1. Cox Regression Analysis of the DDR Pathway Signature in 545 Patients in the Pooled Validation Cohorts
Characteristic
BCR-free Survival Metastasis-free Survival Overall Survival
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
UVA 1.89 (1.44-2.48) 5.01E-06 1.88 (1.33-2.67) 3.91E-04 1.90 (1.32-2.72) 5.15E-04
MVA
DDR pathway signature (high risk vs low risk) 1.71 (1.29-2.28) <.001 1.56 (1.08-2.25) .02 1.69 (1.16-2.47) .006
Age 0.99 (0.97-1.01) .21 0.99 (0.96-1.02) .45 1.02 (0.99-1.05) .20
PSA
<10 (Low risk) 1 [Reference] 1 [Reference] 1 [Reference]
10-20 (Intermediate risk) 1.47 (1.07-2.02) .02 1.21 (0.80-1.84) .37 0.87 (0.57-1.34) .53
>20 (High risk) 1.83 (1.26-2.66) .001 1.78 (1.09-2.91) .02 1.31 (0.78-2.18) .31
Gleason score
6 (Low risk) 1 [Reference] 1 [Reference] 1 [Reference]
7 (Intermediate risk) 1.97 (0.98-3.94) .06 8.84 (1.21-64.60) .03 0.98 (0.47-2.07) .96
8-10 (High risk) 3.77 (1.85-7.70) <.001 19.98 (2.71-147.35) .003 2.06 (0.96-0.42) .06
SMS, + vs − 1.13 (0.84-1.51) .42 1.14 (0.79-1.64) .49 1.30 (0.89-1.90) .18
SVI 1.55 (1.16-2.09) .003 1.46 (1.00-2.11) .05 1.07 (0.73-1.57) .72
ECE 1.44 (1.04-2.00) .03 1.64 (1.04-2.57) .03 1.54 (0.97-2.45) .07
LNI 0.64 (0.38-1.07) .09 1.07 (0.59-1.94) .81 1.31 (0.68-2.54) .42
Abbreviations: BCR, biochemical recurrence; DDR, DNA damage and repair;
ECE, extracapsular extension; HR, hazard ratio; LNI, lymph node involvement;
MVA, multivariate analysis; PSA, prostate-specific antigen; SMS, surgical margin
status; SVI, seminal vesicle invasion; UVA, univariate analysis.
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pathwaypatterns in thishigh-riskprostatecancercohort.These
DDR pathway patterns are better correlatedwith themolecu-
lar variablesAR andERG than clinical variables (Gleason, PSA,
age), indicating the DDR pathways can provide additional in-
formation independentof the clinical variables. Indeed,many
of the individualpathways, andaDDRpathwaysignature,have
statistically significant prognostic association with both me-
tastasis-free and overall survival. Importantly, we also con-
firmed that the DDR pathways are rarely affected by muta-
tion. These findings demonstrate that DDRpathway profiling
is a promising tool in themanagement of prostate cancer, and
we have built a nomogram that would ease its use.
DNA damage and repair pathway profiling also yielded
interesting tumor biology insights that may have profound
translational impacts. AR and ERG have links to DDR
pathways,19,20 including direct functional interaction as
shown by our group and others.16,17,21 These in vitro findings
are reflected in the positive correlation between many DDR
pathways and the AR pathway signature or ERG, thus sup-
porting the validity of our pathway profiling approach. Clini-
cally, sensitivity to PARP-1 inhibitors has been linked to
homologous recombination deficiency from BRCA1 and
BRCA2 mutations, but there are many roads to “BRCAness,”
including overexpression of the prostate long noncoding
RNA PCAT-1.22 Homologous recombination molecular defi-
ciencies may be difficult to comprehensively assay. There-
fore, detecting homologous recombination deficiency
directly with a pathway profiling approach is particularly
desirable as PARP-1 inhibitors gain traction in prostate can-
cer with the promising results in the Phase II TOPARP trial.23
The 2 homologous recombination gene sets used in this
study showed disparate results, which is not surprising
based on the fact that they were designed to reflect different
aspects of homologous recombination as indicated by their
names and confirmed by reviewing the member genes
(eTable 1 in the Supplement). Homologous recombination
gene set N is a more comprehensive representation, while
homologous recombination gene set M focuses on
replication-independent homologous recombination. The
stronger positive correlation between homologous recombi-
nation gene set Mmay thus imply that AR preferentially uses
replication-independent homologous recombination. The
interplay between these gene sets needs to be studied fur-
ther to accurately model the complexity of the homologous
recombination pathway for use in patients.
Ourpathwayprofilingapproachandour findingshavesev-
eral important similarities and differences with existing lit-
erature. Consistentwith our findings, overexpression of DNA
repair geneshas been shown to associatewithmetastatic pro-
gression across several other cancer types.24 Intriguingly, we
found that the DDR pathways appear to play a slightly dispa-
rate role in patients depending on age, though a larger cohort
of patients 70 years or older would be required to fully ex-
plore and identify the difference. This is consistent with, and
provides some explanation for, the findings of 2 studies18,25
totaling more than 8000 patients, which show that older pa-
tients with prostate cancer have better outcomes after radio-
therapy thanyoungerpatients.While there arenoconcrete ex-
planations for this finding, itmaybe reasonable tohypothesize
that older patients have an increased competing risk of death
whichprecludesdiseaseprogression, althoughHamstra et al18
show a difference in prostate cancer–specific mortality, indi-
cating thatothermechanismsmustbepresent.However, there
are intriguingbasic research findings thataging resultsnotonly
in joint stiffness but also perhaps in stiffening at the cellular
level that reduces metastatic potential.26 These results indi-
cate that furtherworkmust bedone to fully understand these
age-relateddifferences.Our approachdiffers from2 recent ef-
forts—the recombination proficiency score and the DNA re-
pair pathway focused score —in that we profiled across entire
pathways, rather than focusing on representative genes.Haz-
ard ratios of our DDR pathway signature for high metastatic
progression risk and overall survival are larger than for either
the recombination proficiency score or the DNA repair path-
wayfocusedscore,11,12 consistentwithourhypothesis that there
is prognostic information in the pathways en bloc.
Whilepathwayprofiling representsanovelapproach, there
are limitations. The exact meaning of pathway gene overex-
pression is ambiguous and is not a direct marker of pathway
activity.Most notably, theremay be a significant discrepancy
betweenDDRgeneexpressionandenzymatic activity, andun-
fortunately high-throughput analysis of enzymatic activity is
not yet possible. There are also limitations of the underlying
retrospective cohorts,whichdonot haveuniformor random-
ized treatmentor follow-up, thoughweattempt to account for
these differences with cohort stratification and inclusion of
clinical and pathologic variables in MVA. It would be reason-
able tohypothesize thatDDRpathwayprofilesmight differ by
ethnicity or between patients with and without a family his-
tory.Unfortunately, familyhistorydatawasnot collected, and,
asnoted in theresults section,ethnicitydatawascollectedonly
for 2 of the 4 cohorts. In this subset of patients, the propor-
tions of DDR signature low-risk vs high-risk patientswere not
different by ethnicity, and comparison of mean DDR signa-
ture score (raw values) by ethnicity was similarly limited and
did not show a clear difference. Thus, prognostic association
by ethnicitywasnot possiblewith the limitednumbers.How-
ever, within these limitations, the distinct pathway pattern
clustersandtheprognosticperformanceofourcompositepath-
way biomarker are provocative.
Conclusions
Our novel patient-level DDR pathway profiling approach re-
vealed distinct DDR pathway clusters and demonstrated that
the DDR pathway profiles have prognostic association with
metastatic progression and overall survival. Thus, DDR path-
wayprofilingmaybeuseful for identifyingprostate cancerpa-
tientswhohave increased risk ofmetastatic progression after
radical prostatectomy. As a biomarker of disease progression,
DDR pathway profilingmay be used to select patients for ear-
lier treatment intensification with approaches such as adju-
vant radiation or systemic therapy and may represent an av-
enue toward improvedpersonalizationof therapy for prostate
cancer patients.
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Invited Commentary
DNADamage and Repair Pathway Profiles as Biomarkers
in High-Risk Prostate Cancer
Sean E. McGuire, MD, PhD
A major challenge for clinicians in the management of pros-
tatecancer isdistinguishingpatientswith indolentdisease from
thosewith aggressive lethal variants of the disease at diagno-
sis. The ability to discriminate between these groups will si-
multaneously allow clini-
cians to avoid overtreatment
of indolentdiseaseand inten-
sify treatment inmenwithag-
gressive disease, aswell as identify themas candidates for fu-
ture biomarker-driven clinical trials. In response to this need,
several genomicbiomarker tests assessing the likelihoodof ag-
gressiveprostatecancerhave recentlybeenbrought to themar-
ket, including Decipher (GenomeDx Biosciences), On-
cotypeDX (Genomic Health), and Prolaris (Myriad Genetics).1
In the year that the 2015 Albert Lasker Basic Medical Re-
searchAwardwasawarded fordiscoveries concerning theDNA
damage response, it is fitting that Evans and colleagues2 re-
port in this issueof JAMAOncology thatpatient levelDNAdam-
ageandrepair (DDR)pathwayprofilesareprognosticafterpros-
tatectomy for high-risk prostate cancer.
Several studies have previously reported that DNA repair
pathwaygeneexpressionscoreshaveprognosticand/orpredic-
tivepower inovarianandnon–small-cell lungcancer (NSCLC).3,4
Evans and colleagues2 hypothesized that DDR pathways hold
prognostic information inprostate cancerandreporton thede-
velopment of a novel patient-level DDRprofiling approach.
Oneof themajor challenges in biomarker development in
prostate cancer is the need for large study sample sizes with
well-curated, long-term outcome data for clinically relevant
endpointssuchasmetastasis-freesurvival (MFS),prostatecan-
cer–specific survival, or overall survival. To address this chal-
lenge, Evans and colleagues2 examined gene expression ar-
rays from 1090 men with high-risk prostate cancer who
underwent prostatectomy at 3 different academic institu-
tionswithamedian followupof 10.3years,divided intoa train-
ing cohort (n = 545) and3pooledvalidation cohorts (n = 545).
Evans and colleagues2 then employed a hybrid pathway-
based approach to focus their analysis on the prognostic role
of DDR pathway gene expression in the training cohort. By
ranking individual geneexpressiondata, theywereable toper-
form gene set enrichment analysis across all 1090 patients
using 17 predefined gene sets representing 9 DDR pathways
fromthestandardcuratedpathwaycollectionsBioCarta,KEGG
(Kyoto Encyclopedia or Genes and Genomics), and Reac-
tome. The output of this analysis is a pathway-specific nor-
malized enrichment score for each individual patient.
Evans and colleagues2 next examined the correlation of
the DDR gene set enrichment with standard clinical and mo-
lecular variables. They observed weak but significant corre-
lation with Gleason score for 16 of 17 DDR gene sets (Spear-
man ρ [ρ], 0.09-0.20) and with age for 7 of 17 gene sets
(ρ, −0.07-0.24). Prostate-specific antigen (PSA) level was
weakly correlated with only 3 of 17 gene sets (ρ, −0.07-0.10).
In sum, the DDR gene sets were only weakly correlated with
the clinical variables examined.
Interestingly,ARexpressionandanARsignaturewereposi-
tively correlated with all of the DDR gene sets (ρ, 0.12-0.82).
This is perhaps not surprising given published reports dem-
onstrating that AR signaling up-regulates DDR pathways.5,6
Somewhat interesting,however, is thestrongassociationof the
DDRgene setswithAR expression and theARpathway signa-
ture but only a weak correlation with PSA, a prototypical AR
regulated gene. This may reflect the high-grade nature of the
tumors in the training set and is highly suggestive that inde-
pendent prognostic information can be obtained by profiling
other factors in addition to PSA level. Interestingly, the 2 ho-
mologous recombination gene sets appeared to reflect diver-
gent correlationswithAR, again suggesting complexity to the
in vivo interactions between prostate cancer molecular driv-
ers and DDR pathways. Correlation with ERG expression was
observed for 13of the 17genesets, althoughthecorrelationwas
weaker than AR (ρ, 0.09-0.25).
Evans and colleagues2 next examined whether the indi-
vidual DDR gene sets had prognostic information by examin-
ing associationswithMFS in the training cohort. Intriguingly,
7 of 9 DDR pathways had statistically significant associations
with worse MFS on univariate analysis. To control for con-
founders, Evansandcolleaguesperformedmultivariate analy-
sis taking into account known clinicopathological factors and
foundthat4of9pathwayswere independentlyassociatedwith
worse MFS, including DNA damage checkpoint, DNA repair,
nucleotide excision repair, and double-stranded break repair
pathways.
Evansandcolleagues2next sought todevelopaprognostic
signaturebiomarker combiningDDRpathwayprofile scores as
acontinuousvariable.Usingthetrainingcohort, theyestablished
a threshold for “high-risk”as thepercentile thatminimized the
univariatePvalueforassociationwithMFS.Uponfurtheranaly-
sis, theyobserved that theDDRpathwaysignaturealsohadsig-
nificant associationwithbiochemical recurrence-free survival
andoverall survival thatwas independent of standard clinical
variablesonmultivariateanalysis. Importantly, in the indepen-
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